Speaker
Description
Auger electron (AE) radiopharmaceutical therapy or Targeted Auger Therapy (TAET) may have the same therapeutic efficacy as alpha-particles for oncologic small disease, with lower risks of normal-tissue toxicity. The seeds of using AE emitters for RPT were planted several decades ago yet it is no anywhere near clinical use. The furthest is probably Tb-161 [1] which a combination of beta emission supplemented with AE (often referred to as Lu-177+) and not pure TAET.
This paper will attempt to give an overview of isotopes considered aspects in terms of half-life, AE energy deposition, co-emission of gamma, theranostic pairs and availability. This is based on recent literature on this topic [2,3].
Lastly the mechanism of action for AE has always been believed to be through double strand breaks in the DNA. It has been recently demonstrated that this may not been universally true in every situation [1,4].
References
1. Borgna F, Haller S, Rodriguez JMM, Ginj M, Grundler PV, Zeevaart JR, Köster U, Schibli R, van der Meulen NP, Müller C. Combination of terbium-161 with somatostatin receptor antagonists-a potential paradigm shift for the treatment of neuroendocrine neoplasms. Eur J Nucl Med Mol Imaging. 2022. doi: 10.1007/s00259-021-05564-0.
2. Bolcaen J, Gizawy MA, Terry SYA, Paulo A, Cornelissen B, Korde A, Engle J, Radchenko V, Howell RW. Marshalling the Potential of Auger Electron Radiopharmaceutical Therapy. J Nucl Med. 2023 1344-1351. doi: 10.2967/jnumed.122.265039.
3. Filosofov D, Kurakina E, Radchenko V. Potent candidates for Targeted Auger Therapy: Production and radiochemical considerations. Nucl Med Biol. 2021 94-95:1-19. doi: 10.1016/j.nucmedbio.2020.12.001.
4. Julie Constanzo and Jean-Pierre Pouget, 7th Theranostics World Congress, 2024, Chile
